GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Ananda Pharma PLC (AQSE:ANA) » Definitions » Inventory-to-Revenue

Ananda Pharma (AQSE:ANA) Inventory-to-Revenue : 0.00 (As of Jul. 2023)


View and export this data going back to 2018. Start your Free Trial

What is Ananda Pharma Inventory-to-Revenue?

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue. Ananda Pharma's Average Total Inventories for the quarter that ended in Jul. 2023 was £0.00 Mil. Ananda Pharma's Revenue for the six months ended in Jul. 2023 was £0.00 Mil.

Ananda Pharma's Inventory-to-Revenue for the quarter that ended in Jul. 2023 stayed the same from Jan. 2023 (0.00) to Jan. 2023 (0.00)

Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Inventory Turnover measures how fast the company turns over its inventory within a year.


Ananda Pharma Inventory-to-Revenue Historical Data

The historical data trend for Ananda Pharma's Inventory-to-Revenue can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Ananda Pharma Inventory-to-Revenue Chart

Ananda Pharma Annual Data
Trend Jan19 Jan20 Jan21 Jan22 Jan23
Inventory-to-Revenue
- - - - -

Ananda Pharma Semi-Annual Data
Jul18 Jan19 Jul19 Jan20 Jul20 Jan21 Jul21 Jan22 Jul22 Jan23 Jul23
Inventory-to-Revenue Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Ananda Pharma's Inventory-to-Revenue

For the Drug Manufacturers - Specialty & Generic subindustry, Ananda Pharma's Inventory-to-Revenue, along with its competitors' market caps and Inventory-to-Revenue data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Ananda Pharma's Inventory-to-Revenue Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Ananda Pharma's Inventory-to-Revenue distribution charts can be found below:

* The bar in red indicates where Ananda Pharma's Inventory-to-Revenue falls into.


;
;

Ananda Pharma Inventory-to-Revenue Calculation

Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.

Ananda Pharma's Inventory-to-Revenue for the fiscal year that ended in Jan. 2023 is calculated as

Inventory-to-Revenue (A: Jan. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (A: Jan. 2022 ) + Total Inventories (A: Jan. 2023 )) / count ) / Revenue (A: Jan. 2023 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=N/A

Ananda Pharma's Inventory-to-Revenue for the quarter that ended in Jul. 2023 is calculated as

Inventory-to-Revenue (Q: Jul. 2023 )
=Average Total Inventories / Revenue
=( (Total Inventories (Q: Jan. 2023 ) + Total Inventories (Q: Jul. 2023 )) / count ) / Revenue (Q: Jul. 2023 )
=( (0 + 0) / 1 ) / 0
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ananda Pharma  (AQSE:ANA) Inventory-to-Revenue Explanation

An increase in Inventory-to-Revenue from one quarter to the next indicates that one of the following is happening:

1. investment in inventory is growing more rapidly than revenue
2. revenue are dropping
No matter which situation is causing the problem, an increase in the Inventory-to-Revenue may signal an oncoming cash flow problem.

Likewise, a decrease in the Inventory-to-Revenue from one quarter to next indicates that one of these is occurring:

1. investment in inventory is shrinking in relation to revenue
2. revenue are increasing
No matter which situation is causing the reduction in the Inventory-to-Revenue, either one suggests that business's inventory levels and its cash flow are effectively managed.

More Related Terms:

1. Days Inventory indicates the number of days of goods in sales that a company has in the inventory.

Ananda Pharma's Days Inventory for the six months ended in Jul. 2023 is calculated as:

Days Inventory=Average Total Inventories (Q: Jul. 2023 )/Cost of Goods Sold (Q: Jul. 2023 )*Days in Period
=0/0*365 / 2
=

2. Inventory Turnover measures how fast the company turns over its inventory within a year.

Ananda Pharma's Inventory Turnover for the quarter that ended in Jul. 2023 is calculated as

Inventory Turnover=Cost of Goods Sold (Q: Jul. 2023 ) / Average Total Inventories (Q: Jul. 2023 )
=0 / 0
=

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Ananda Pharma Inventory-to-Revenue Related Terms

Thank you for viewing the detailed overview of Ananda Pharma's Inventory-to-Revenue provided by GuruFocus.com. Please click on the following links to see related term pages.


Ananda Pharma Business Description

Traded in Other Exchanges
N/A
Address
60 Gracechurch Street, 6th Floor, London, GBR, EC3V 0HR
Ananda Pharma PLC is focused on the development of cannabinoid therapies for the treatment of a range of complex conditions. The company is developing NHS-approved and MHRA-licensed cannabinoid medicines for the treatment of drug-resistant epilepsies and specific inflammatory pain conditions (starting with CIPN & endometriosis) and HFpEF heart failure.

Ananda Pharma Headlines

No Headlines